Data gathered: November 27
Alternative Data for Heron Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 5 | Sign up | Sign up | Sign up |
| Sentiment | 90 | Sign up | Sign up | Sign up |
| Webpage traffic | 7,000 | Sign up | Sign up | Sign up |
| Employee Rating | 62 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 6 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 7,289 | Sign up | Sign up | Sign up |
| Twitter Mentions | 22 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Lobbying Cost | $17,000 | Sign up | Sign up | Sign up |
| Business Outlook | 26 | Sign up | Sign up | Sign up |
| Linkedin Employees | 175 | Sign up | Sign up | Sign up |
About Heron Therapeutics
Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care.
| Price | $1.16 |
| Target Price | Sign up |
| Volume | 825,550 |
| Market Cap | $173M |
| Year Range | $1.06 - $3.86 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Principal Financial Group Inc. Acquires 84,205 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)November 26 - ETF Daily News |
|
Heron Therapeutics, Inc. (NASDAQ:HRTX) Position Increased by GSA Capital Partners LLPNovember 16 - ETF Daily News |
 |
Heron Therapeutics Inc (HRTX) Q3 2024 Earnings Call Highlights: Strategic Initiatives Drive ...November 12 - Yahoo |
 |
Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street EstimatesNovember 11 - Yahoo |
 |
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue EstimatesNovember 11 - Yahoo |
|
Heron Therapeutics: Q3 Earnings SnapshotNovember 11 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 33M | 33M | 23M | -4.8M | 0 | 0.000 |
| Q2 '24 | 36M | 38M | 26M | -9.2M | -5.8M | -0.060 |
| Q1 '24 | 35M | 35M | 26M | -3.2M | -4.1M | -0.020 |
| Q4 '23 | 31M | 34M | 24M | -11M | -9.5M | -0.070 |
| Q3 '23 | 31M | 43M | 13M | -25M | -24M | -0.170 |
Insider Transactions View All
| Forbes William P filed to buy 79,000 shares at $1.1. November 21 '23 |
| Duarte Ira filed to buy 85,000 shares at $0.9. November 17 '23 |
| Forbes William P filed to buy 54,000 shares at $0.9. November 20 '23 |
| Collard Craig A filed to buy 186,496 shares at $0.9. November 17 '23 |
| Morgan Adam filed to buy 1,162,891 shares at $1.4. July 25 '23 |
Similar companies
Read more about Heron Therapeutics (HRTX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Heron Therapeutics?
The Market Cap of Heron Therapeutics is $173M.
What is the current stock price of Heron Therapeutics?
Currently, the price of one share of Heron Therapeutics stock is $1.16.
How can I analyze the HRTX stock price chart for investment decisions?
The HRTX stock price chart above provides a comprehensive visual representation of Heron Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Heron Therapeutics shares. Our platform offers an up-to-date HRTX stock price chart, along with technical data analysis and alternative data insights.
Does HRTX offer dividends to its shareholders?
As of our latest update, Heron Therapeutics (HRTX) does not offer dividends to its shareholders. Investors interested in Heron Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Heron Therapeutics?
Some of the similar stocks of Heron Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.